Ken Y Yoneda

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

Molecular cancer therapeutics

Therapeutic advances in respiratory disease

This page only lists publications with an associated author ORCID identifier.

Publications

Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin overcomes resistance to tyrosine kinase inhibitors in patient-derived, oncogene-driven lung adenocarcinoma models. Molecular cancer therapeutics (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Chinh Phan, Forrest Jespersen, Caroline Weipert, Tianhong Li, Ken Y Yoneda
Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience. Therapeutic advances in respiratory disease 16 (2022)